Please assess the completion status of the following clinical trial:

Trial Title: Effects of E-cigarettes (ECIGs) on Pulmonary Inflammation and Behavior in HIV Infected Smokers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Self-reported smoking of ≥10 cigarettes/day for \>2yrs~2. Smoke regular filtered cigarettes or machine-rolled cigarettes with a filter~3. Have expired CO concentrations of ≥10ppm or morning urinary cotinine \>100ng/ml (as measured with NicAlert)~   * If present in the afternoon with CO concentration \>10ppm then no cotinine test~  * If less than \<10 then urinary continine~4. No serious quit attempt in the prior 3 months. This includes use of any FDA approved smoking cessation medication (varenicline, bupropion \[used specifically as a quitting aid\], patch, gum, lozenge, inhaler, and nasal spray) in the past 3 months as an indication of treatment seeking~5. No plans to quit in the next 3 months (set quit date, designated method, etc.)~6. Participants must be interested in substituting their normal combustible tobacco products with ECIG for 4 weeks~7. Willing and able to give informed consent and adhere to visit/protocol schedules~8. Reported method of birth control for at least 3 months prior to enrollment for women of child bearing potential~9. Read and write in English~   HIV-positive patients must meet the following additional inclusion criteria:~10. Currently receive HIV care at the Duke Infectious Diseases Clinic~11. Receiving stable ART treatment (i.e., no ART class changes or changes in dose in response to poor virological control) for \>9 months with viral loads \<200 copies/mL~Exclusion Criteria:~1. Alcohol intoxication measured by positive BAL (any detectable level)~2. Acute psychiatric symptoms (e.g. mania, hallucinations) preventing completion of the study procedures~3. Current use of nicotine replacement or other pharmacotherapy for smoking cessation~4. Positive pregnancy test for women (pregnant women will be referred for smoking cessation) and/or nursing women~5. Use of other tobacco products (e.g. chew tobacco, snuff) on \>10 of the past 30 days will exclude patients to ensure they are primarily cigarette smokers~6. Use of hand-rolled, roll your own cigarettes~7. Use of marijuana or cigars \>2 times/week will be excluded from the study. Subjects using marijuana ≤2 times/week will be required to refrain for the duration of the protocol.~8. Positive urine drug screen other than marijuana or currently prescribed medications.~9. Known allergy to propylene glycol or vegetable glycerin (potential constituents of ECIG)~10. Use of an ECIG for 5 or more within 30 days or any use in the past 7 days~11. Patients with a formal clinical or spirometry diagnosis of co-existing inflammatory airway conditions of COPD and/or asthma or underlying illnesses that may result in altered lung function (bronchiectasis, prior surgical lung resection, extensive cavitary infectious disease, etc.)~12. An ED visit or inpatient admission for a primary respiratory diagnosis or treatment with antibiotics within 60 days of enrollment~13. History of any systemic or inhaled corticosteroids within 3 months~14. Regular substance abuse or inpatient treatment for these in the past 6 months~15. Poorly controlled concomitant conditions that pose additional procedure risk as determined by the investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: t

Study Arms:
- ECIGS (Type: ACTIVE_COMPARATOR): Subjects will receive e-cigarettes for a total of 4 weeks. A mobile contingency management (mCM) procedure will be used to provide monetary reinforcement for biochemically verified abstinence from combustible cigarettes. After 4 weeks, subjects will be allowed to transition back to their chosen combustible cigarette product for an additional 2 weeks. Respiratory assessments will occur at study arm assignment (Visit 1) to establish baseline measures of lung function, oxidative stress, and systemic inflammation, repeated again 4 weeks after transition to ECIG (Visit 4) and again 2 weeks after stopping ECIG (Visit 5). Neuro-cognitive and behavioral assessments will occur at Visits 2, 3, 4 and 5.
- Usual brand (Type: ACTIVE_COMPARATOR): Subjects will receive their usual brand of combustible cigarettes for a total of 4 weeks. A mobile contingency management mCM procedure will be used. Respiratory assessments will occur at study arm assignment (Visit 1) to establish baseline measures of lung function, oxidative stress, and systemic inflammation, repeated again 4 weeks later (Visit 4) and again 2 weeks later (Visit 5). Neuro-cognitive and behavioral assessments will occur at Visits 2, 3, 4 and 5.

Based on this trial design, predict the completion outcome and termination type (if applicable).